Effects of Atorvastatin on hs-CRP,IL-6,TNF-α and endothelium-dependent vasodilation in elderly patients with hypertension
Duan Xiaoyan
Abstract
Duan Xiaoyan
Abstract
Objective To investigate the influence of different doses atorvastatin on the serum lipid and High Sensitive C-Reactive Protein(hs-CRP),IL-6,TNF-α and endothelium-dependent vasodilation in elderly patients with hypertension.Methods 84 elderly patients with hypertension were divided into three groups randomly:the control group,the atorvastatin treatment group A(10 mg/d) and the atorvastatin treatment group B(20 mg/d).Each group received regular anti-hypertension treatment,the atorvastatin treatment groups were administered orally atrovastatin.Therapeutic time was 8 weeks.Blood pressure,serum total cholesterol(TC),low density lipoprotein-cholesterol(LDL-C),hs-CRP,IL-6,TNF-α contents and endothelium-dependent vasodilation were measured before and after therapy.Results Compared with before therapy,blood pressure after therapy in the three groups were significantly decreased(P0.05 or P0.01).The TC,LDL-C,hs-CRP,IL-6,TNF-α after therapy in the three groups were decreased,and the atorvastatin treatment groups were significantly decreased(P0.05 or P0.01).The endothelium-dependent vasodilation was significantly improved in the three groups(P0.05 or P0.01).Compared with the control group,the TC,LDL-C and hs-CRP in groups A and B,the IL-6,TNF-α in the group B were significantly decreased(P0.05 or P0.01);Compared with the group A,hs-CRP,LDC-C in group B was significantly decreased(P0.01).The endothelium-dependent vasodilation in group B improved more significantly than group A.Conclusion Atorvastatin can effectively decrease the serum lipid,alleviate vascular in flammation response and improve endothelium-dependent vasodilation in elderly patients with hypertension,and the doses of 20 mg/d is better than 10 mg/d.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective To investigate the influence of different doses atorvastatin on the serum lipid and High Sensitive C-Reactive Protein(hs-CRP),IL-6,TNF-α and endothelium-dependent vasodilation in elderly patients with hypertension.Methods 84 elderly patients with hypertension were divided into three groups randomly:the control group,the atorvastatin treatment group A(10 mg/d) and the atorvastatin treatment group B(20 mg/d).Each group received regular anti-hypertension treatment,the atorvastatin treatment groups were administered orally atrovastatin.Therapeutic time was 8 weeks.Blood pressure,serum total cholesterol(TC),low density lipoprotein-cholesterol(LDL-C),hs-CRP,IL-6,TNF-α contents and endothelium-dependent vasodilation were measured before and after therapy.Results Compared with before therapy,blood pressure after therapy in the three groups were significantly decreased(P0.05 or P0.01).The TC,LDL-C,hs-CRP,IL-6,TNF-α after therapy in the three groups were decreased,and the atorvastatin treatment groups were significantly decreased(P0.05 or P0.01).The endothelium-dependent vasodilation was significantly improved in the three groups(P0.05 or P0.01).Compared with the control group,the TC,LDL-C and hs-CRP in groups A and B,the IL-6,TNF-α in the group B were significantly decreased(P0.05 or P0.01);Compared with the group A,hs-CRP,LDC-C in group B was significantly decreased(P0.01).The endothelium-dependent vasodilation in group B improved more significantly than group A.Conclusion Atorvastatin can effectively decrease the serum lipid,alleviate vascular in flammation response and improve endothelium-dependent vasodilation in elderly patients with hypertension,and the doses of 20 mg/d is better than 10 mg/d.
Key concepts: Atorvastatin, Medicine, Vasodilation, Internal medicine, Endothelium, Blood pressure, Tumor necrosis factor alpha, C-reactive protein